Download PDF
Thromb Haemost 1977; 38(04): 0751-0775
DOI: 10.1055/s-0038-1651896
Original Article
Schattauer GmbH

Participation of Hageman Factor Dependent Pathways in Human Disease States

Robert W. Colman
*   Coagulation Unit of the Hematology-Oncology Section, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
,
Patrick Y. Wong
**   Department of Gastroenterology, Albany Medical College, Albany, New York, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
04 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

Abnormalities of Hageman factor dependent pathways have been described in a wide variety of human disease states. Congenital deficiencies of factor XII (Hageman trait) prekallikrein (Fletcher trait) and high molecular weight kininogen (Williams, Fitzgerald and Flaujeac traits) although resulting in profound in vitro changes, do not cause in vivo difficulties. In contrast, deficiency of Cl esterase inhibitor (hereditary angioedema) results in significant morbidity and mortality. Acquired diseases may exhibit decreased synthesis of these three proteins in cirrhosis and dengue fever. In vivo activation of factor XII initiated pathways occur in septic shock, disseminated or localized intravascular coagulation, typhoid fever, polycythemia vera, hyperbetalipoproteinemia, coronary artery disease, nephrotic syndrome, transfusion reactions, hemodialysis and extracorporeal bypass. Activation of both the intrinsic system and tissue mediators contribute to the vasomotor phenomena in carcinoid syndrome and postgastrectomy dumping. Roles for factor XII, prekallikrein and kininogen have been suggested in gouty arthritis, allergic disorders and cystic fibrosis but the evidence is not yet convincing in these disorders.

 

  • References

  • 1 Austen K. F, Sheffer A. L. 1965; Detection of hereditary angioneurotic edema by demonstration of reduction of second component of complement. New England Journal of Medicine 272: 649.
    CrossrefPubMedGoogle Scholar
  • 2 Bagdasarian A, Talamo R. C, Colman R. W. 1973; a Isolation of high molecular weight activators of prekallikrein. Journal of Biological Chemistry 248: 3456.
    PubMedGoogle Scholar
  • 3 Bagdasarian A, Lahiri B, Colman R. W. 1973; b Origin of the high molecular weight activator of prekallikrein. Journal of Biological Chemistry 248: 1142.
    PubMedGoogle Scholar
  • 4 Bagdasarian A, Lahiri B, Talamo R. C, Wong P. Y, Colman R. W. 1974; Immunochemical studies of plasma kallikrein. Journal of Clinical Investigation 54: 1444.
    CrossrefPubMedGoogle Scholar
  • 5 Bell G. 1965; Peripheral circulation during the dumping syndrome. British Journal of Surgery 52: 300.
    CrossrefPubMedGoogle Scholar
  • 6 Blümel G, Klauser G, Neumayr A, Peschl L, Rottenbacker-Teubner H. 1967; Die Bedeutung der Plasmakinine bei der Entstehung des Dumping-Syndromes. Medizinische Welt 2751.
    PubMedGoogle Scholar
  • 7 Bokisch V. A, Top jr. F. H, Russel P. K. 1973; The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. New England Journal of Medicine 289: 996.
    CrossrefPubMedGoogle Scholar
  • 8 Bouma B. N, Griffin J. H. 1977; Human prekallikrein (plasminogenproactivator): Purification, characterization and activation by activated factor XII. Thrombosis and Haemostasis 38: 136.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Briseld K, Qvigstaid E. K, Engelstad M, Kageriov P, Lange-Nielsen F. 1976; Assay of factors of the kinin systems in plasma from patients with specific exogenous allergies. Acta Allergologica 31: 297.
    CrossrefPubMedGoogle Scholar
  • 10 Brocklehurst W. E, Zeitlin I. J. 1967; Determination of plasma kinin and kininogen levels in man. Journal of Physiology 191: 417.
    CrossrefPubMedGoogle Scholar
  • 11 Brockway W. J, Castellino F. J. 1971; The mechanism of the inhibition ofplasmin activity by E-aminocaproic add. Journal of Biological Chemistry 246: 4641.
    PubMedGoogle Scholar
  • 12 Burrowes C. E, Movat H. V, Soltay M. J. 1971; The kinin system of human plasma VI. The action of plasmin. Proceedings of the Society of Experimental Biological Medidne 138: 959.
    PubMedGoogle Scholar
  • 13 Busch G. J, Kobayashi K, Hollenberg N. K, Birtch A. G, Colman R. W. 1975; b Hyperacute renal allograft rejection in the primate. Intrarenal effects of heparin and associated net release of factor VIII activity and kallikrein activation. American Journal of Pathology 80: 1.
    PubMedGoogle Scholar
  • 14 Busch G. J, Martins A. C. P, Hollenberg N. K, Wilson R. E, Colman R. W. 1975; a Aprímate model of hyperacute renal allograft rejection. American Journal of Pathology 79: 31.
    PubMedGoogle Scholar
  • 15 Carvalheira A. F, Welsch U, Pearse A. G. E. 1968; Cytochemical and ultrastructural observations on the argentaffin and argyrophil cells of the gastrointestinal tract in mammals and their place in the APUD series of polypeptide-secreting cells. Histochemie 14: 33.
    CrossrefPubMedGoogle Scholar
  • 16 Carvalho A. C, Colman R. W, Lees R. S. 1974; a Platelet function in hyperlipoproteinemia. New England Journal of Medidne 290: 434.
    PubMedGoogle Scholar
  • 17 Carvalho A. G, Colman R. W, Lees R. S. 1974; b Clofibrate reversal of platelet hypersensitivity in hyperlipoproteinemia. Circulation 50: 570.
    CrossrefPubMedGoogle Scholar
  • 18 Carvalho A. C, Ellman L. 1976; Activation of the coagulation system in polycythemia vera. Blood 47: 669.
    PubMedGoogle Scholar
  • 19 Carvalho A. C, Lees R. S, Vaillancourt R. A, Cabral R. B, Weinberg R. M, Colman R. W. 1976; Intravascular coagulation in hyperlipoproteinemia. Thrombosis Research 8: 843.
    CrossrefPubMedGoogle Scholar
  • 20 Carvalho A. C, Lees R. S, Vaillancourt R. A, Colman R. W. 1977; Effect of clofibrate on intravascular coagulation in hyperlipoproteinemia. Circulation 56: 114.
    CrossrefPubMedGoogle Scholar
  • 21 Castania A, Rothschild A. M. 1974; Lowering of kininogen in rat blood by adrenalin. Inhibition by sympatholytic agents, heparin and aspirin. British Journal of Pharmacology 50: 375.
    CrossrefPubMedGoogle Scholar
  • 22 Cochrane C. G, Revak S. D, Wuepper K. D. 1973; Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. Journal of Experimental Medicine 138: 1564.
    CrossrefPubMedGoogle Scholar
  • 23 Cochrane C. G, Wuepper K. D. 1971; The first component of the kinin forming system in human and rabbit plasma. Journal of Experimental Medicine 134: 986.
    CrossrefPubMedGoogle Scholar
  • 24 Cohen S. H, Halstead S. B. 1966; Shock associated with dengue infection. I Clinical and physiologic manifestations of dengue hemorrhagic fever in Thailand 1964. Journal of Pediatrics 68: 448.
    CrossrefPubMedGoogle Scholar
  • 25 Collier H. O. J. 1966. Self-antagonism of broncho construction induced by bradykinin and angiotension. In: Erdos E. G, Back N, Sicuteri F, Wilde A. F. (eds.) Hypotensive Peptides. Springer; Berlin – Heidelberg – New York: 305.
    Google Scholar
  • 26 Colman R. W. 1969; Activation of plasminogen by human plasma kallikrein. Biochemical Biophysical Research Communications 35: 273.
    CrossrefPubMedGoogle Scholar
  • 27 Colman R. W. 1976; Hereditary angioedema and heparin therapy. Annals of Internal Medicine 85: 399.
    CrossrefPubMedGoogle Scholar
  • 28 Colman R. W, Bagdasarían A, Talamo R. C, Scott C. F, Seavey M, Guimaraes J. A, Pierce J. V, Kaplan A. P. 1975; Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. Journal of Clinical Investigation 56: 1650.
    CrossrefPubMedGoogle Scholar
  • 29 Colman R. W, Braun W. E, Busch G. J, Dammin G. J, Merrill J. P. 1969; a Coagulation studies in hyperacture and other forms of renal allogrant rejection. New England Journal of Medicine 281: 685.
    CrossrefPubMedGoogle Scholar
  • 30 Colman R. W, Girey G, Galvanek E. G, Busch G. J. 1972. Human renal allografts: The protective effects of heparin, kallikrein activation and fibrinolysis during hyperacture rejection. In: Thomas C. C. Symposium on Coagulation Problems in Transplanted Organs. Illinois: 87.
    Google Scholar
  • 31 Colman R. W, Mason J. W, Sherry S. 1969; b The Kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observation in disease states. Annals of Internal Medicine 71: 763.
    CrossrefPubMedGoogle Scholar
  • 32 Colman R. W, Mattler L, Sherry S. 1969; c Studies on the prekallikrein (kallikreinogen) – kallikrein enzyme system of human plasma II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. Journal of Clinical Investigation 48: 23.
    CrossrefPubMedGoogle Scholar
  • 33 Colman R. W, Scoh C. F, Edelman R, Gilman R. H. 1978 Plasma kallikrein activation and inhibition during typhoid fever. Journal of Clinical Investigation. (in press).
    PubMedGoogle Scholar
  • 34 Colman R. W, Wong P. Y, Talamo R. C. 1976. Kallikrein-kinin system in carcinoid and postgastrectomy dumping syndrome. In: Pisano J. J, Austen K. F. Chemistry and Biology of the Kallikrein-Kinin System in Health and Disease. Fogarty International Center; Proceeding, No. 27 487.
    Google Scholar
  • 35 Cuevas P, Fine J. 1973; Production of fatal endotoxin shock by vasoactive substances. Gastroenterology 64: 285.
    PubMedGoogle Scholar
  • 36 Currimbhoy A, Vinciguerru V, Palakavongs P, Kuslansky P, Degnan T. J. 1976; Fletcher factor deficiency and myocardial infarction. American Journal of Clinical Pathology 65: 970.
    CrossrefPubMedGoogle Scholar
  • 37 Cuschieri A, Onabanjo O. A. 1971; Kinin release after gastric surgery. British Medical Journal 3: 565.
    CrossrefPubMedGoogle Scholar
  • 38 Delbianco P. L, Fanciullacci M, Frarchi G. 1972; Plasmatickininogen in acute hepatitis andin liver cirrhosis. Advances in Experimental Medicine and Biology 21: 453.
    PubMedGoogle Scholar
  • 39 Doeglas H. M. G, Bleumink E. 1974; Familial cold urticaria. Archives of Dermatology 110: 382.
    CrossrefPubMedGoogle Scholar
  • 40 Doeglas H. M. G, Bleumink E. 1975; Protease inhibitors in plasma of patients with chronic urticaria. Archives of Dermatology 111: 979.
    CrossrefPubMedGoogle Scholar
  • 41 Donaldson V. H. 1968; Mechanism of activation of Cl esterase in hereditary angioedema plasma in vitro: Role of Hageman factor clot promoting agent. Journal of Experimental Medicine 127: 411.
    CrossrefPubMedGoogle Scholar
  • 42 Donaldson V. H, Evans R. R. 1963; A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of C’l esterase. American Journal of Medicine 35: 35.
    PubMedGoogle Scholar
  • 43 Donaldson V. H, Glueck H. I, Miller M. A, Movat H. Z, Habal F. 1976; Kininogen deficiency in Fitzgerald trait: Role of high molecular weight kininogen in clotting and fibrinolysis. Journal of Laboratory and Clinical Medicine 89: 327.
    PubMedGoogle Scholar
  • 44 Donaldson V. H, Ratnoff O. D, Dias da Silva W, Rosen F. S. 1969; Permeability-increasing activity of hereditary angioneurotic edema. II. Mechanism of formation and partial characterization. Journal of Clinical Investigation 48: 642.
    CrossrefPubMedGoogle Scholar
  • 45 Donaldson V, Rosen F. S. 1964; Action of complement in hereditary angioneurotic edema: Role of C’l esterase. Journal of Clinical Investigation 43: 2204.
    CrossrefPubMedGoogle Scholar
  • 46 Donaldson V. H, Rosen F. S, Bing D. H. 1977; Role of the second component of complement (C2) in hereditary angioneurotic edema (HANE) plasma. Clinical Research 25: 520A.
    PubMedGoogle Scholar
  • 47 Edelman R, Nimmannitya S, Colman R. W, Talamo R. C, Top F. H. 1975; Evaluation of the plasma kinin system in dengue hemorrhagic fever. Journal of Laboratory and Clinical Medicine 86: 410.
    PubMedGoogle Scholar
  • 48 Erdos E. G. 1969 The kallikrein-kinin-kininasë system. Cellular and human mechanisms in anaphylaxis and allergy. Edited by Movat Vasel H. Z, Karger S. 233.
    PubMedGoogle Scholar
  • 49 Erdos E. G, Miwa I. 1968; Effect of endotoxin shock on plasma kallikrein-kinin system of the rabbit. Federation Proceedings 27: 92.
    PubMedGoogle Scholar
  • 50 Fanciullacci M, Galli P, Monetti P, Pela I, Delbianco P. L. 1975; Prekallikrein and kallikrein inhibitor in liver cirrhosis and hepatitis. Advances in Experimental Medicine and Biology 70: 201.
    PubMedGoogle Scholar
  • 51 Forsmann W. G, Orei L, Pictet R, Renold A. E, Roviller C. 1969; The endocrine cells in the epithelium of the gastrointestinal mucosa of the rat. Journal of Cell Biology 40: 692.
    CrossrefPubMedGoogle Scholar
  • 52 Frank M. M, Sergent J. S, Kane M. A, Alling D. W. 1972; Epsilon aminocapric add therapy of hereditary angioedema. A double blind study. New England Journal of Medicine 281: 808.
    PubMedGoogle Scholar
  • 53 Gadek J. E, Hosea S. W, Gelford S. A, Frank M. M. 1977; Cl inhibitor phenotypes in hereditary angioedema. Genetic implications of successful Danazol therapy. Clinical Research 25: 357a.
    PubMedGoogle Scholar
  • 54 Galletti R, Matassi L, Chiarini P, Vecchiet L, Buzzelli G, Marra N. 1968; Plasma kinin activity in cirrhotic subjects. Lo Sperimentale 118: 253.
    PubMedGoogle Scholar
  • 55 Gigli I, Mason J. W, Colman R. W, Austen K. F. 1970; Interaction of plasma kallikrein with the Cl inhibitor. Journal of Immunology 104: 574.
    PubMedGoogle Scholar
  • 56 Girey G. J. D, Talamo R. C, Colman R. W. 1972; The kinetics of release of bradykinin by kallikrein in normal plasma. Journal of Laboratory and Clinical Medicine 80: 465.
    PubMedGoogle Scholar
  • 57 Gjonnaess H. 1972; a Cold promoted activation of factor VII: I Evidence for existence of an activation. Thrombosis et Diathesis Haemorrhagica 28: 155.
    PubMedGoogle Scholar
  • 58 Gjonnaess H. 1972; b Cold promoted activation of factor VII: III Relation to the kallikrein system. Thrombosis et Diathesis Haemorrhagica 28: 182.
    PubMedGoogle Scholar
  • 59 Glueck H. I, Roehill W. 1966; Myocardial infarction in a patient with Hageman (factor XII) defect. Annals of Internal Medicine 64: 390.
    CrossrefPubMedGoogle Scholar
  • 60 Goldsmith G. H, Stern R. C, Saito H, Ratnoff O. D. 1977; Normal plasma agrinine esterase and the Hageman factor (factor XII)-prekallikrein-kininogen system in cystic fibrosis. Journal of Laboratory and Clinical Medicine 89: 131.
    PubMedGoogle Scholar
  • 61 Green J, Talamo R. C, Colman R. W. 1974; Kinetics of kinin release in canine plasma. American Journal of Physiology 226: 784.
    PubMedGoogle Scholar
  • 62 Griffin J. H, Cochrane C. G. 1976; Mechanisms for the involvement of high molecular weight kininogenin surface dependent reactions of Hageman factor. Proceedings of the National Academy of Sciences 73: 2554.
    CrossrefPubMedGoogle Scholar
  • 63 Habal F. M, Movat H. Z, Burrowes C. E. 1974; Isolation of two functionally different kininogens from human plasma. Separation from proteolytic inhibitors and interaction with plasma kallikrein. Biochemistry Pharmacology 23: 2291.
    CrossrefPubMedGoogle Scholar
  • 64 Harpel P. C. 1970; Cl inactivator inhibition by plasmin. Journal of Clinical Investigation 49: 568.
    CrossrefPubMedGoogle Scholar
  • 65 Hasimoto K, Warka J, Kohn R. N, Wilkens H. J, Steger R, Back N. 1975; Thevasopeptide kinin system in acute clinical cardiac disease. Advances in Experimental Medicine and Biology 70: 245.
    PubMedGoogle Scholar
  • 66 Hathaway W. E, Belhanson L. P, Hathaway H. S. 1965; Evidence for a new thromboplastin factor: Case report, coagulation studies and physio chemical studies. Blood 26: 521.
    PubMedGoogle Scholar
  • 67 Hattersley P. G, Hayes D. 1970; Fletcher factor deficiency; report of three unrelated cases. British Journal of Haematology 18: 411.
    CrossrefPubMedGoogle Scholar
  • 68 Herman C. M, Oshima G, Erdos E. G. 1974; The effect of adrenocorticoid pretreatment on kinin system and coagulation response to septic shock in the baboon. Journal of Laboratory and Clinical Medicine 84: 731.
    PubMedGoogle Scholar
  • 69 Herzheimer H, Streseman E. 1961; Effect of bradykinin aerosol in guinea pigs and man. Journal of Physiology 158: 38P.
    PubMedGoogle Scholar
  • 70 Hirsch E. F, Nagajima T, Oshima G, Erdos E. G, Herman C. M. 1974; Kinin system responses in sepsis after trauma in man. Journal of Surgical Research 17: 147.
    CrossrefPubMedGoogle Scholar
  • 71 Hoak J. C, Swenson L. W, Warner E. D. 1966; Myocardial infarction associated with severe factor XII deficiency. Lancet II: 884.
    PubMedGoogle Scholar
  • 72 Hollenberg N. K, Retik A. B, Rosen S. M, Murray J. E, Merrillm J. P. 1968; The role of vasoconstriction in the ischemia of renal allograft rejection. Transfusion 6: 59.
    PubMedGoogle Scholar
  • 73 Honig G. R, Lindley A. 1971; Deficiency of Hageman factor (factor XII) in patients with the nephrotic syndrome. Journal of Pediatrics 78: 633.
    CrossrefPubMedGoogle Scholar
  • 74 Izaka K, Morichi S, Fujita Y, Hasegawa E. 1975; A kininogen-like substance in unheated human plasma proteins. Transfusion 15: 46.
    PubMedGoogle Scholar
  • 75 Izaka K, Tsutsui E, Mina Y, Hasegawa E. 1974; A bradykinin-like substance heat treated human plasma protein solution. Transfusion 14: 242.
    CrossrefPubMedGoogle Scholar
  • 76 Johnson L. P, Jesseph J. E. 1961; Evidence for a humoral etiology of the dumping syndrome. Surgical Forum 12: 316.
    PubMedGoogle Scholar
  • 77 Jonasson O, Becker E. L. 1966; Release of kallikrein from guinea pig lung during anaphylaxis. Journal of Experimental Medicine 123: 509.
    CrossrefPubMedGoogle Scholar
  • 78 Kallen R. J, Soo-Kwang L. 1975; A study of the plasma kinin-generating system in children with the minimal lesion, idiopathic nephrotic syndrome. Pediatric Research 9: 705.
    CrossrefPubMedGoogle Scholar
  • 79 Kaplan A. P, Austen K. F. 1970; A prealbumin activator of prekallikrein. Journal of Immunology 105: 802.
    PubMedGoogle Scholar
  • 80 Kaplan A. P, Austen K. F. 1971; A prealbumin activator of prekallikrein II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. Journal of Experimental Medicine 133: 696.
    CrossrefPubMedGoogle Scholar
  • 81 Kaplan A. P, Austen K. F. 1972; b The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. Journal of Experimental Medicine 136: 1378.
    CrossrefPubMedGoogle Scholar
  • 82 Katori M, Nagaoka H. 1976 Significance of the kinin system and inhibition ofkinin formation by kallikrein inhibition in extracorporeal circulation in open-heart surgery patients. In: Chemistry and Biology of the Kallikrein-Kinin System in Health and Disease. (eds.) Pisano J. L, Austen K. I. 553.
    PubMedGoogle Scholar
  • 83 Kellermeyer R. W. 1964. Activation of Hageman factor by sodium urate crystals. Proceedings of conference on gout and purine metabolism. (ed.) Gutman A. B. New York: Grune and Stratton; 741.
    Google Scholar
  • 84 Kellermeyer R. W, Breckenridge R. T. 1965; The inflammatory process in acute gouty arthritis. I. Activation of Hageman factor by sodium urate crystals. Journal of Laboratory and Clinical Medicine 65: 307.
    PubMedGoogle Scholar
  • 85 Kellermeyer R. W, Graham R. C. 1968; Kinins-possible physiologic and pathologic roles in the man. New England Journal of Medicine 279: 859.
    CrossrefPubMedGoogle Scholar
  • 86 Kellermeyer R. W, Nagg G. B. 1975; Chemical mediators of inflammation in acute gouty arthritis. Arthritis and Rheumatism (Suppl.) 18: 765.
    CrossrefPubMedGoogle Scholar
  • 87 Klemperer M. R, Donaldson V. H, Rosen F. S. 1968; Effect of C’l esterase on vascular permeability in man. Journal of Clinical Investigation 47: 604.
    CrossrefPubMedGoogle Scholar
  • 88 Laake K, Vennerod A. M. 1974; Factor XII-induced fibrinolysis studies on the separation of prekallikrein, plasminogen proactivator and factor XI in human plasma. Thrombosis Research 4: 285.
    CrossrefPubMedGoogle Scholar
  • 89 Lacombe M. J, Varet B, Levy J. P. 1975; A hitherto underscribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor): Case report and coagulation studies. Blood 46: 761.
    PubMedGoogle Scholar
  • 90 Lacombe N. J. 1975; Deficit constitutionel en un nouveau facteur de la coagulation intervenant au niveau de contact: le facteur “Flaujeac”. C. F. Hebd. Seances Academy of Sciences 280: 1039.
    PubMedGoogle Scholar
  • 91 Lahiri B, Talamo R. C, Mitchell B, Bagdasarian A, Colman R. W, Rosenberg R. 1976; Antithrombin III an inhibitor of human kallikrein. Archives of Biochemistry and Biophysics 175: 737.
    CrossrefPubMedGoogle Scholar
  • 92 Landerman N. S. 1962; Hereditary angioneurotic edema. I. Case reports and review of literature. Journal of Allergy 33: 316.
    CrossrefPubMedGoogle Scholar
  • 93 Landerman N. S, Webster M. E, Becker E. L, Ratcliffe H. D. 1962; Hereditary angioneurotic edema. Journal of Allergy 33: 330.
    CrossrefPubMedGoogle Scholar
  • 94 Lange L. G, Carvalho A. C, Bagdasarian A, Lahiri B, Colman R. W. 1974; Activation of Hageman factor in the nephrotic syndrome. American Journal of Medicine 56: 565.
    CrossrefPubMedGoogle Scholar
  • 95 Lieberman J. 1974; Plasma arginine esterase activity in cystic fibrosis. American Reviews of Respiratory Diseases 109: 399.
    PubMedGoogle Scholar
  • 96 Liu C. Y, Scott C. F, Bagdasarian A, Pierce J. V, Kaplan A. P, Colman R. W. 1977; Potentiation of the function of Hageman factor fragments by high molecular weight kininogen. Journal of Clinical Investigation 60: 7.
    CrossrefPubMedGoogle Scholar
  • 97 Lopas H, Birndorf N. I, Bell Jr. C. E, Robboy S, Colman R. W. 1973; Immune hemolytic transfusion in monkeys: Activation of the kallikrein system. American Journal of Physiology 225: 372.
    PubMedGoogle Scholar
  • 98 Lukjan H, Hofman J, Kiersnoroska B, Bielawiec M, Chyrek-Borowska S. 1972; The kinin system in allergic states. Allergic and Immunologic Band 18: 25.
    PubMedGoogle Scholar
  • 99 Lutcher C. L. 1976; Reid trait: A new expression of high molecular weight kininogen (HMW-Kininogen) deficiency. Clinical Research 24: 47 abstract.
    PubMedGoogle Scholar
  • 100 MacDonald J. M, Webster Jr. M. M, Tennyson C. H, Drapanos T. 1969; Serotonin and bradykinin in the dumping syndrome. American Journal of Surgery 117: 204.
    CrossrefPubMedGoogle Scholar
  • 101 MacKay M. E, Maycock W, Silk E, Cambridge B. S. 1965; Studies on fibrinogen fractions isolated from human plasma by precipitation with cold ether I. Plasma kinin formation by the activation of contaminated plasminogen. British Journal of Haematology 11: 563.
    CrossrefPubMedGoogle Scholar
  • 102 Mandle R, Colman R. W, Kaplan A. P. 1976; Identification of prekallikrein and high molecular weight (HMW) kininogen as a circulating complex in human plasma. Proceedings of the National Academy of Sciences 73: 4179.
    CrossrefPubMedGoogle Scholar
  • 103 Mandle R, Kaplan A. P. 1977 Hageman factor substrates II. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participating in Hageman factor dependent proteolysis. Journal of Biological Chemistry. in press.
    PubMedGoogle Scholar
  • 104 Mason D. T, Melmon K. L. 1965; Effects of bradykinin on forearm venous tone and vascular resistance in man. Circulation Research 17: 106.
    CrossrefPubMedGoogle Scholar
  • 105 Mason J. W, Colman R. W. 1971; The role of Hageman factor in disseminated intravascular coagulation induced by sepsis neoplasia or liver disease. Thrombosis et Diathesis Haemorrhagica 26: 325.
    PubMedGoogle Scholar
  • 106 Mason J. W, Kleeberg U. R, Dolan P, Colman R. W. 1970; Plasma kallikrein and Hageman factor in gram negative bacteremia. Annals of Internal Medicine 73: 545.
    CrossrefPubMedGoogle Scholar
  • 107 Matheson R. T, Miller D. R, Lacombe M. J, Han Y. N, Iwanaga S, Kato H, Wuepper K. D. 1976; Reconstitution with highly purified bovine high molecular weight-kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular weight-kininogen. Journal of Clinical Investigation 58: 1395.
    CrossrefPubMedGoogle Scholar
  • 108 McGrath J. M, Stewart G. J. 1969; The effects of endotoxin on vascular endothelium. Journal of Experimental Medicine 129: 833.
    CrossrefPubMedGoogle Scholar
  • 109 Meier H. K, Webster M. E, Mandle R, Colman R. W, Kaplan A. P. 1977; a Enhancement of the surface dependent Hageman factor activation by high molecular weight kininogen. Journal of Clinical Investigation 60: 18.
    CrossrefPubMedGoogle Scholar
  • 110 Meier J. L, Scott C. F, Mandle Jr. R, Webster M. E, Pierce J. V, Colman R. W, Kaplan A. P. 1977; Requirements for contact activation of human Hageman factor. Annals of the New York Academy of Sciences 283: 93.
    CrossrefPubMedGoogle Scholar
  • 111 Melmon K. L, Lovenberg W, Sjoerdsma A. 1965; Characteristics of carcinoid tumor kallikrein: identification of lysyl-bradykinin as a peptide it produces in vitro. Clinical Chimica Acta 12: 292.
    CrossrefPubMedGoogle Scholar
  • 112 Melmon K. L, Webster M. E, Goldfinger S. E, Seegmiller J. E. 1967; The presence of a kinin in inflammatory synovial effusion from arthritis of varying etiology. Arthritis and Rheumatism 10: 13.
    CrossrefPubMedGoogle Scholar
  • 113 Miller R. L, Reichgott M. J, Melmon K. L. 1973; Biochemical mechanisms of generation of bradykinin by endotoxin. Journal of Infectious Diseases 125 (Suppl.) 144.
    PubMedGoogle Scholar
  • 114 Minna J. D, Robboy S. J, Colman R. W. 1974. Disseminated intravascular coagulation in man. Thomas, C. C.; Illinois.:
    Google Scholar
  • 115 Movat H. Z, Belorenzo N. L, Mustard J. F, Helmel G. 1966; Activation of Hageman factor and vascular permeability factor in serum by Ag-Ab precipitates. Federation Proceedings 25: 682.
    PubMedGoogle Scholar
  • 116 Nies A. S, Forsyth R. P, Williams H. E, Melmon K. L. 1968; Contribution of kinin to endotoxin shock in unanesthetized Rhesus monkeys. Circulation Research 22: 155.
    CrossrefPubMedGoogle Scholar
  • 117 Oates J. A, Melmon K, Sjoerdsma A, Gillespie L, Mason D. T. 1964; Release of a kinin peptide in the carcinoid syndrome. Lancet I: 514.
    PubMedGoogle Scholar
  • 118 Oates J. A, Pettinger W. A, Doctor R. B. 1966; Evidence for the release of bradykinin in carcinoid syndrome. Journal of Clinical Investigation 45: 173.
    CrossrefPubMedGoogle Scholar
  • 119 O’Donnell T. F, Clowes Jr. G. H, Talamo R. C, Colman R. W. 1976; Kinin activation in the blood of patients with sepsis. Surgery, Gynecology and Obstetrics 143: 539.
    PubMedGoogle Scholar
  • 120 Paskhina T. S, Krinskaya A. V. 1974; Uprochennyimetod opredeleniia kallikreinogena i kallikreinia v syvorotke (plasme) krovi cheloveka v nosme i pri nekotorykh pathologichiecheskikh sostonianiiakh. Vopr Medicine Khim 20 (06) 660.
    PubMedGoogle Scholar
  • 121 Pence H. L, Evon R, Guerney L. H, Gerhard R. G. 1974; Prophylactic use of epsilon aminocaproic acid for oral surgery in a patient with hereditary angioneurotic edema. Journal of Allergy and Clinical Immunology 53: 298.
    CrossrefPubMedGoogle Scholar
  • 122 Peterson D. W, Hamilton W. H, Lilyblade A. L. 1971; Hereditary susceptability to dietary induction of gout in selected lines of chickens. Journal of Nutrition 101: 347.
    CrossrefPubMedGoogle Scholar
  • 123 Phelps P, McCarty jr. D. J. 1966; Crystal-induced inflammation in canine joints II. Importance of polymorphonuclear leukocytes. Journal of Experimental Medicine 124: 115.
    CrossrefPubMedGoogle Scholar
  • 124 Phelps P, Prockop D. J, McCarty D. T. 1966; Crystal-induced inflammation in canine joints III. Evidence against bradykinin as a mediator of inflammation. Journal of Laboratory and Clinical Medicine 68: 433.
    PubMedGoogle Scholar
  • 125 Pickering R. J, Kelly J. R, Goode R. A, Gewitz H. 1969; Replacement therapy in hereditary angioedema: Successful treatment of two patients with fresh frozen plasma. Lancet I: 326.
    PubMedGoogle Scholar
  • 126 Pierce J. V, Guimaraes J. A. 1977. Further characterization of highly purified human plasma kininogens. In: Chemistry and Biology of the kallikrein-kinin system in Health and Disease. U.S. Government Printing Office; Washington, D.C.: 121.
    Google Scholar
  • 127 Pitt B, Mason J, Conti C. R. 1969; Observations on the plasma kallikrein system during myocardial ischemia. Transactions of Association of American Physicians 82: 98.
    PubMedGoogle Scholar
  • 128 Radcliffe R, Bagdasarían A, Colman R. W, Nemerson Y. 1977 Activation of factor VII by Hageman factor fragments. Blood. in press.
    PubMedGoogle Scholar
  • 129 Rao G. J. S, Nadler H. L. 1973; Deficiency of trypsin-like activity in saliva of patients with cystic fibrosis. Journal of Pediatrics 80: 573.
    PubMedGoogle Scholar
  • 130 Rao G. J. S, Nadler H. L. 1974; Arginine esterase in cystic fibrosis of the pancreas. Pediatric Research 8: 684.
    CrossrefPubMedGoogle Scholar
  • 131 Rao G. J. S, Nadler H. L. 1975; Deficiency of arginine esterase in cystic fibrosis of the pancreas: Demonstration of the proteolytic nature of the activity. Pediatric Research 9: 739.
    CrossrefPubMedGoogle Scholar
  • 132 Rao G. J. S, Posner L. A, Nadler H. L. 1972; Deficiency of kallikrein activity in plasma of patients with cystic fibrosis. Science 177: 610.
    CrossrefPubMedGoogle Scholar
  • 133 Rapaport S, Aas K, Owen P. A. 1955; Effect of glass upon the activity of various plasma clotting factors. Journal of Clinical Investigation 34: 9.
    CrossrefPubMedGoogle Scholar
  • 134 Ratnoff O. D. 1966. The biology and pathology of the initial coagulation reactions. In: Brown E. B, Moore C. V. (ed.) Progress in Hematology. 5 204 Grune and Stratton, Inc.; New York.:
    Google Scholar
  • 135 Ratnoff O. D, Busce R. J, Sheon R. P. 1968; The demise of John Hageman. New England Journal of Medicine 279: 760.
    CrossrefPubMedGoogle Scholar
  • 136 Ratnoff O. D, Colopy J. E. 1955; A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. Journal of Clinical Investigation 34: 601.
    PubMedGoogle Scholar
  • 137 Rafnoff O. D, Davie E. W, Mallet D. L. 1961; Study on the action of Hageman factor: Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. Journal of Clinical Investigation 40: 803.
    CrossrefPubMedGoogle Scholar
  • 138 Ratnoff O. D, Pensky J, Ogston D, Naff G. B. 1969; The inhibition of plasmin, plasma kallikrein, plasma permeability factor and the C lr subcomponent of the first component of complement by serum Cl esterase inhibitor. Journal of Experimental Medicine 129: 315.
    CrossrefPubMedGoogle Scholar
  • 139 Revak S. D, Cochrane C. G, Johnston A. R. 1973; Structure of Hageman factor in its native and activated forms. Federation Proceedings 32: 845.
    PubMedGoogle Scholar
  • 140 Robinson J. A, Klodyncky M. L, Loeb H. S, Racic M. R, Gunnar R. M. 1975; Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurement in man. American Journal of Medicine 59: 61.
    CrossrefPubMedGoogle Scholar
  • 141 Rochae Silva M, Antonio A. 1960; Release of bradykinin and the mechanism of production of a “Thermic” edema (45°C) in the rat’s paw. Medical Experimentia, (Basel) 3: 371.
    PubMedGoogle Scholar
  • 142 Rochae Silva M, Beraldo W. T, Rosenfeld G. 1949; Bradykinin, hypotensive and smooth muscle stimulator released from plasma globin by snake venoms and by trypsin. American Journal of Physiology 156: 261.
    PubMedGoogle Scholar
  • 143 Ruddy S, Gigli I, Austen K. F. 1972; The complement system of man. New England Journal of Medicine 287: 545.
    CrossrefPubMedGoogle Scholar
  • 144 Saito H, Goldsmith G. Waldmann 1976; Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and disease in various animal plasma. Blood 48: 941.
    PubMedGoogle Scholar
  • 145 Saito H, Ratnoff O. D. 1974; Inhibition of normal clotting and Fletcher factor activity by rabbit anti-kallikrein antiserum. Nature 248: 597.
    CrossrefPubMedGoogle Scholar
  • 146 Saito H, Ratnoff R, Waldmann Abraham J. P. 1975; Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface mediated reasctions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability (PF/dil). Journal of Clinical Investigation 55: 1082.
    CrossrefPubMedGoogle Scholar
  • 147 Sardesai V. M, Rosenberg J. C. 1974; Proteolysis and bradykinin turnover in endotoxin shock. Journal of Trauma 14: 945.
    CrossrefPubMedGoogle Scholar
  • 148 Schiffman S, Lee P. 1974; Preparation characterization, and activation of a highly purified factor XI: Evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII. British Journal of Haematology 27: 101.
    CrossrefPubMedGoogle Scholar
  • 149 Schiffman S, Lee P. 1975; Partial purification and characterization of contact activation cofactor. Journal of Clinical Investigation 56: 1082.
    CrossrefPubMedGoogle Scholar
  • 150 Seki T, Makajime T, Erdos E. G. 1972; Colon kallikrein, its relation to the plasma enzyme. Biochemistry Pharmacology 21: 1227.
    CrossrefPubMedGoogle Scholar
  • 151 Sherry S, Alkjaersig N, Fletcher A. P. 1966; Observations on spontaneous arginine and lysine esterase activity of human plasma and their relation to Hageman factor. Thrombosis et Diathesis Haemorrhagica (Suppl.) 20: 243.
    PubMedGoogle Scholar
  • 152 Sicuteri F, Antonini F. M, Delbianco P. L, Franchi G, Currodi C. 1972; Prekallikrein and kallikrein inhibitor in plasma of patients affected by recent myocardial infarction. Advances in Experimental Medicine and Biology 21: 445.
    PubMedGoogle Scholar
  • 153 Sicuteri F, Delbianco P. L, Franciullacci M. 1970; Kinins in the pathogenesis of cardiogenic shock and pain. Advances in Experimental Medicine and Biology 9: 315.
    PubMedGoogle Scholar
  • 154 Snyder A, Hand M. R, Gewenz H. 1974; A rapid pH state assay for plasma prekallikrein and fluctuations in disease. International Archives of Allergy 47: 400.
    CrossrefPubMedGoogle Scholar
  • 155 Soltay M. J, Movat H. Z, Ozge-Anwar A. H. 1971; The kinin system of human plasma V. The probable derivation of prekallikrein activator from activated Hageman factor (XIIa). Proceedings of the Society of Experimental Biology and Medicine 138: 952.
    PubMedGoogle Scholar
  • 156 Soter N. A, Austen K. R, Gigli I. 1975; Inhibition by epsilon amino-caproic acid of the activation of the first component of the complement system. Journal of Immunology 114: 928.
    PubMedGoogle Scholar
  • 157 Stewart D, Blendis I. M, Williams R. 1972; Studies on the prekallikrein-bradykinin system in liver disease. Journal of Clinical Pathology 25: 410.
    CrossrefPubMedGoogle Scholar
  • 158 Talamo R. C, Haber E, Austen K. F. 1969; A radioimmunoassay of bradykinin in plasma and synovial fluid. Journal of Laboratory and Clinical Medicine 74: 816.
    PubMedGoogle Scholar
  • 159 Thune P, Ryan T. J, Powell S. M, Ellis R. J. 1976; The cutaneous reactions to kallikrein, prostaglandin and thurfyl nicotinate in chronic urticaria and the effect of polyphloretin phosphate. Acta Dermatology Benereol (Stockholm) 56: 217.
    PubMedGoogle Scholar
  • 160 Van Arman C. G, Bohidar N. R. 1976 Role of the kallikrein kinin system in inflammation. In: Chemistry and Biology of the Kallikrein-kinin System in Health and Disease. Pisano J. J, Austen K. F. (ed.) 471.
    PubMedGoogle Scholar
  • 161 Vassalio G, Solcia E, Cappella C. 1969; Light and electro microscopic identification of several types of endocrine cells in the gastrointestinal mucosa of the rat. Z Zellforsch 98: 333.
    CrossrefPubMedGoogle Scholar
  • 162 Veltkamp J. M, Demler H. C, Locliger E. A. 1965; Detection of heterozygotes for factor VIII, IX and XII deficiency. Thrombosis et Diathesis Haemorrhagica 13 (Suppl.) (17) 181.
    PubMedGoogle Scholar
  • 163 Vennerod A. M, Laake K. 1976; Prekallikrein and plasminogen proactivator: Absence of plasminogen proactivator in Fletcher factor deficient plasma. Thrombosis Research 8: 519.
    CrossrefPubMedGoogle Scholar
  • 164 Wardle E. N, Piercy D. A. 1972; Studies of the contact activation in haemodialysis. Journal of Clinical Pathology 25: 1045.
    CrossrefPubMedGoogle Scholar
  • 165 Webster M. E, Guinaraes J. A, Kaplan A. P, Colman R. W, Pierce J. V. 1976. Activation of surface bound Hageman factor: Pre-eminent role of high molecular weight kininogen and evidence for a new factor. In: Kinins: Pharmacodynamics and biological roles. Sicuteri F, Back N, Haberland G. L. (eds.). Plenum Publishing Company; New York.:
    Google Scholar
  • 166 Webster M. E, Pierce J. V. 1973; Activators of Hageman factor (Factor XII): Identification and relationship to kallikrein-kinin system. Federation Proceedings 32: 845.
    PubMedGoogle Scholar
  • 167 Werle S, Vogel R, Kaliampetsos G. 1963 Über das Kallikrein der Darmwand und seine Beziehung zum Blutkallikreingehalt bei Störungen der Darmfunktion. In: Second Work Congress of Gastroenterology. (eds.). Schmid E, Tomenius J, Walkinson G, Basel S, Karger A. G. 788.
    PubMedGoogle Scholar
  • 168 Wiegershausen B, Hennighausen G, Klausch B. 1970; Plasma kininogen levelin myocardial infarction. Advances in Experimental Medicine and Biology 8: 221.
    PubMedGoogle Scholar
  • 169 Wong P. Y, Colman R. W, Talamo R. C, Babior B. M. 1972; Kallikrein-bradykinin system in chronic alcoholic liver disease. Annals of Internal Medicine 77: 205.
    CrossrefPubMedGoogle Scholar
  • 170 Wong P. Y, Talamo R. C, Babior B. M, Raymond G. G, Colman R. W. 1974; Kallikrein-kinin system is postgastrectomy dumping syndrome. Annals of Internal Medicine 80: 577.
    CrossrefPubMedGoogle Scholar
  • 171 Wong P. Y, Talamo R. C, Williams G. H, Colman R. W. 1975; Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and up-right posture. Journal of Clinical Investigation 55: 691.
    CrossrefPubMedGoogle Scholar
  • 172 Wong P. Y, Talamo R. C, Colman R. W, Williams G. H. 1976. Dependence of plasma bradykinin on state of sodium balance. In: Chemistry and Biology of Kallikrein-kinin System in Health and Disease. Pisano J. J, Austen K. F. (ed.). Fogarty International Center Proceedings no. 27 Washington, D.C: U.S. Government Printing Office; chapter 50 415.
    Google Scholar
  • 173 Wong P. Y, Talamo R. C, Williams G. H. 1977 Kallikrein-kinin and renin-angiotensin systems in functional renal failure in cirrhosis of the liver. Gastroenterology. (in press).
    PubMedGoogle Scholar
  • 174 Wuepper K. D. 1972. Biochemistry and biology of components of the plasma kinin-forming system. In: Inflammation: mechanisms and control. Lepow I. N, Ward P. A. (eds.) New York: Academic Press; 93.
    Google Scholar
  • 175 Wuepper K. D. 1973; Prekallikrein deficiency in man. Journal of Experimental Medicine 138: 1345.
    CrossrefPubMedGoogle Scholar
  • 176 Zeitlin I. J. 1970. Kinin release associated with the gastrointestinal tract in bradykinin and related kinins. In: Sicuteri F, Rocha E. S, Back N. (eds.) New York: Plenum Press; 329.
    Google Scholar
  • 177 Zeitlin I. J, Sharma J. N, Brooks P. M, Dick W. C. 1976. An effect of indomethacin on raised plasma kininogen levels in rheumatoid patients. In: Chemistry and Biology of the Kallikrein-kinin System in Health and Disease. Pisano J. J, Austen K. F. (eds.). DHEW; 483.
    Google Scholar
  • 178 Zeitlin I. J, Singh Y. N, Lembeck R, Theiller M. 1976; The molecular weights of plasma and intestinal kallikreins in rats. Archives of Pharmacology 293: 159.
    CrossrefPubMedGoogle Scholar
  • 179 Zeitlin I. J, Smith A. N. 1966; 5-hydroxyindoles and kinins in the carcinoid and dumping syndrome. Lancet II: 986.
    PubMedGoogle Scholar